AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
February 19 2019 - 8:00AM
Business Wire
Endorsement complements the company’s ongoing
commitment to physician education
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatment for atrial fibrillation (Afib) and left atrial appendage
management, today announced that The Society of Thoracic Surgeons
(STS) has endorsed its Advanced Ablation course for both physicians
and fellows. The course provides surgeons and other medical
professionals with a comprehensive overview of the treatment of
Afib during cardiac surgery.
Founded in 1964, STS is a not-for-profit organization
representing more than 7,500 cardiothoracic surgeons, researchers,
and allied health care professionals worldwide who are dedicated to
ensuring the best possible outcomes for surgeries of the heart,
lungs, and esophagus, as well as other procedures within the chest.
Its mission is to enhance the ability of cardiothoracic surgeons to
provide the highest quality patient care through education,
research, and advocacy.
“We want to thank the STS for this recent endorsement of our
educational programs,” said Michael Carrel, President and Chief
Executive Officer of AtriCure. “One of the foundational elements of
our company is education, and we have partnered with leading
physician faculty around the world to deliver robust programming.
We share a common vision with the STS and look forward to
continuing to train and educate as many physicians as possible on
concomitant surgical Afib treatment.”
Since receiving PMA approval for the Isolator® Synergy™ Ablation
System for the treatment of persistent and long-standing persistent
Afib during cardiac surgery in 2011, AtriCure has trained over
2,300 surgeons, cardiologists, and other allied health
professionals in the United States.
“AtriCure’s receipt of STS’ endorsement is validation of the
physician education curriculum offered by the company,” said Dr.
James L. Cox, Professor of Cardiac Surgery at Northwestern
University in Chicago. “Since I have been involved with AtriCure, I
have seen firsthand their commitment to providing world-class
educational courses, which has in turn led to more physicians
treating patients. I’m confident that continuing these efforts will
lead to more and more of my colleagues seeing the benefits of
concomitant Afib surgery, so that no patient gets left without the
opportunity to be treated.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip Left Atrial Appendage (LAA)
Exclusion System products are the most widely sold LAA management
devices worldwide, with more than 170,000 implanted to date. For
more information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190219005080/en/
Valerie Storch-WillhausMedia RelationsSenior Director, Corporate
Marketing and Communications(612)
605-3311vstorch-willhaus@AtriCure.com
Andy WadeInvestor RelationsSenior Vice President and Chief
Financial Officer(513) 755-4564awade@AtriCure.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2023 to Apr 2024